Linding Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Linding Wang has a total of 96 co-authors. Here are the top co-authors by number of shared publications:
Chang Zhou
The Key Laboratory of Microbiology and Parasitology of Anhui Province, The Key Laboratory of Zoonoses of High Institutions in Anhui, Department of Microbiology and Parasitology, School of Basic Medical Sciences Anhui Medical University Hefei Anhui China
5 shared publicationsHuanwu Wu
The Key Laboratory of Microbiology and Parasitology of Anhui Province, The Key Laboratory of Zoonoses of High Institutions in Anhui, Department of Microbiology and Parasitology, School of Basic Medical Sciences Anhui Medical University Hefei Anhui China
3 shared publicationsWenli Li
The Key Laboratory of Microbiology and Parasitology of Anhui Province, The Key Laboratory of Zoonoses of High Institutions in Anhui, Department of Microbiology and Parasitology, School of Basic Medical Sciences Anhui Medical University Hefei Anhui China
3 shared publicationsYan Liu
3 shared publicationsYiting Zhang
The Key Laboratory of Microbiology and Parasitology of Anhui Province, The Key Laboratory of Zoonoses of High Institutions in Anhui, Department of Microbiology and Parasitology, School of Basic Medical Sciences Anhui Medical University Hefei Anhui China
3 shared publicationsYulin Zhu
Department of Pediatrics The First Affiliated Hospital of Anhui Medical University Hefei Anhui China
3 shared publications
Latest Publications
- Open Access
Potential Role of Oral Nitrate Bioactivation in Interindividual Exercise Responses to Dietary Nitrate: A Narrative Review
Background: Equivalent doses of dietary nitrate often yield highly heterogeneous exercise responses across individuals. Efficient enterosalivary nitrate-to-nitrite conversion is dependent on oral commensal bacteria, representing a critical upstream step that may drive downstream variability in biomarker profiles and exercise outcomes. This review evaluates whether variation at the oral bioactivation step helps account for differences in downstream biomarkers and exercise performance. Methods: We conducted a structured narrative review of PubMed and Web of Science covering 1 January 2006 to 31 March 2026 using predefined keywords related to dietary nitrate, oral bioactivation, oral microbiota, enterosalivary pathway, and exercise performance. Human supplementation trials, antibacterial mouthwash perturbation studies, investigations evaluating oral function, and supporting case-report and preclinical evidence were included when they linked nitrate exposure, oral microbial activity or salivary nitrite kinetics, and physiological or exercise performance outcomes. Results: Oral bacteria are essential contributors to efficient enterosalivary nitrate-to-nitrite conversion. Associations between oral function and nitrite availability, as well as selected physiological measures, are reasonably consistent. However, direct evidence linking oral function to athlete performance remains sparse. No athlete trial identified in the present search has concurrently measured oral function, tracked serial nitrate/nitrite kinetics, and paired these data with a reliable performance test and prespecified mediation analysis. A rise in salivary nitrite therefore confirms engagement of the enterosalivary pathway, but it does not reliably identify an ergogenic responder. Current evidence does not yet allow quantitative estimation of how much between-person performance variability is attributable to oral bioactivation. Conclusions: Oral nitrate-reducing function remains a biologically plausible modifier of exercise responses, but it is not a validated predictive biomarker. Integrated athlete trials are needed to trace the full pathway from nitrate exposure to performance outcomes and to quantify within-person and between-person variation.
Open AccessPotential Role of Oral Nitrate Bioactivation in Interindividual Exercise Responses to Dietary Nitrate: A Narrative Review
Background: Equivalent doses of dietary nitrate often yield highly heterogeneous exercise responses across individuals. Efficient enterosalivary nitrate-to-nitrite conversion is dependent on oral commensal bacteria, representing a critical upstream step that may drive downstream variability in biomarker profiles and exercise outcomes. This review evaluates whether variation at the oral bioactivation step helps account for differences in downstream biomarkers and exercise performance. Methods: We conducted a structured narrative review of PubMed and Web of Science covering 1 January 2006 to 31 March 2026 using predefined keywords related to dietary nitrate, oral bioactivation, oral microbiota, enterosalivary pathway, and exercise performance. Human supplementation trials, antibacterial mouthwash perturbation studies, investigations evaluating oral function, and supporting case-report and preclinical evidence were included when they linked nitrate exposure, oral microbial activity or salivary nitrite kinetics, and physiological or exercise performance outcomes. Results: Oral bacteria are essential contributors to efficient enterosalivary nitrate-to-nitrite conversion. Associations between oral function and nitrite availability, as well as selected physiological measures, are reasonably consistent. However, direct evidence linking oral function to athlete performance remains sparse. No athlete trial identified in the present search has concurrently measured oral function, tracked serial nitrate/nitrite kinetics, and paired these data with a reliable performance test and prespecified mediation analysis. A rise in salivary nitrite therefore confirms engagement of the enterosalivary pathway, but it does not reliably identify an ergogenic responder. Current evidence does not yet allow quantitative estimation of how much between-person performance variability is attributable to oral bioactivation. Conclusions: Oral nitrate-reducing function remains a biologically plausible modifier of exercise responses, but it is not a validated predictive biomarker. Integrated athlete trials are needed to trace the full pathway from nitrate exposure to performance outcomes and to quantify within-person and between-person variation.
- Top Cited PapersOpen Access
Gut Microbiota and Exercise-Induced Fatigue: A Narrative Review of Mechanisms, Nutritional Interventions, and Future Directions
Background: Exercise-induced fatigue (EIF) impairs performance and recovery and may contribute to overreaching/overtraining and adverse health outcomes. Beyond classical explanations (substrate depletion, metabolite accumulation, oxidative stress), accumulating evidence indicates that the gut microbiota modulates fatigue-related physiology through metabolic, immune, barrier, and neurobehavioral pathways. Methods: We conducted a structured narrative review of PubMed and Web of Science covering 1 January 2015 to 30 November 2025 using predefined keywords related to EIF, gut microbiota, recovery, and nutritional interventions. Human studies, animal experiments, and mechanistic preclinical work (in vivo/in vitro) were included when they linked exercise load, microbial features (taxa/functions/metabolites), and fatigue-relevant outcomes. Results: Across models, high-intensity or prolonged exercise is consistently associated with disrupted gut homeostasis, including altered community structure, reduced abundance of beneficial taxa, increased intestinal permeability, and shifts in microbial metabolites (e.g., short-chain fatty acids). Evidence converges on four interconnected microbiota-mediated pathways relevant to EIF: (1) energy availability and metabolic by-product clearance; (2) redox balance and inflammation; (3) intestinal barrier integrity and endotoxemia risk; and (4) central fatigue and exercise motivation via microbiota–gut–brain signaling. Nutritional strategies—particularly targeted probiotics, prebiotics/plant polysaccharides, and selected bioactive compounds—show potential to improve fatigue biomarkers and endurance-related outcomes, although effects appear context-dependent (exercise modality, baseline fitness, diet, and baseline microbiota). Conclusions: Current evidence supports a mechanistic role of the gut microbiota in EIF and highlights microbiota-targeted nutrition as a promising adjunct for recovery optimization. Future work should prioritize causal validation (e.g., fecal microbiota transplantation and metabolite supplementation), athlete-focused randomized trials with standardized fatigue endpoints, and precision approaches that stratify individuals by baseline microbiome features and training load.
Top Cited PapersOpen AccessGut Microbiota and Exercise-Induced Fatigue: A Narrative Review of Mechanisms, Nutritional Interventions, and Future Directions
Background: Exercise-induced fatigue (EIF) impairs performance and recovery and may contribute to overreaching/overtraining and adverse health outcomes. Beyond classical explanations (substrate depletion, metabolite accumulation, oxidative stress), accumulating evidence indicates that the gut microbiota modulates fatigue-related physiology through metabolic, immune, barrier, and neurobehavioral pathways. Methods: We conducted a structured narrative review of PubMed and Web of Science covering 1 January 2015 to 30 November 2025 using predefined keywords related to EIF, gut microbiota, recovery, and nutritional interventions. Human studies, animal experiments, and mechanistic preclinical work (in vivo/in vitro) were included when they linked exercise load, microbial features (taxa/functions/metabolites), and fatigue-relevant outcomes. Results: Across models, high-intensity or prolonged exercise is consistently associated with disrupted gut homeostasis, including altered community structure, reduced abundance of beneficial taxa, increased intestinal permeability, and shifts in microbial metabolites (e.g., short-chain fatty acids). Evidence converges on four interconnected microbiota-mediated pathways relevant to EIF: (1) energy availability and metabolic by-product clearance; (2) redox balance and inflammation; (3) intestinal barrier integrity and endotoxemia risk; and (4) central fatigue and exercise motivation via microbiota–gut–brain signaling. Nutritional strategies—particularly targeted probiotics, prebiotics/plant polysaccharides, and selected bioactive compounds—show potential to improve fatigue biomarkers and endurance-related outcomes, although effects appear context-dependent (exercise modality, baseline fitness, diet, and baseline microbiota). Conclusions: Current evidence supports a mechanistic role of the gut microbiota in EIF and highlights microbiota-targeted nutrition as a promising adjunct for recovery optimization. Future work should prioritize causal validation (e.g., fecal microbiota transplantation and metabolite supplementation), athlete-focused randomized trials with standardized fatigue endpoints, and precision approaches that stratify individuals by baseline microbiome features and training load.
- Open Access
- 1 January 2026
- Published by Wiley in Canadian Journal of Infectious Diseases and Medical Microbiology
- Vol. 2026 (1)
KSHV Seropositivity Associates With Impaired Immune Reconstitution in Virally Suppressed HIV
Background: Kaposi’s sarcoma–associated herpesvirus (KSHV) seropositivity is prevalent in people with HIV (PWH), yet its association with immune reconstitution during long‐term ART remains unclear. Methods: In this retrospective cohort study, we reviewed the records of 209 virally suppressed PWH (VL < 50 copies/mL) after ≥ 2 years of ART. Participants were stratified based on their KSHV serostatus (IgG+). Data on immune parameters were extracted from laboratory reports corresponding to the 2‐year post‐ART time point. Results: KSHV seropositive individuals exhibited significantly lower CD4 + counts (101.5 vs. 316.0 cells/μL; p < 0.001), reduced CD4/CD8 ratios (0.26 vs. 0.60; p < 0.001), and elevated IL‐6 (9.78 vs. 5.46 pg/mL; p < 0.001). Multivariate analysis identified IL‐6 as an independent predictor of seropositivity (OR = 1.238; p < 0.001). The combination of CD4 + (≤ 126 cells/μL) and IL‐6 (> 5.83 pg/mL) showed superior diagnostic accuracy for KSHV seropositivity (AUC = 0.832). Conclusion: KSHV seropositivity correlates with impaired immune reconstitution in virally suppressed PWH. CD4 + and IL‐6 may jointly serve as a screening tool for KSHV serostatus assessment, though their utility for detecting active infection requires further study.
- 1 January 2026
- Published by Wiley in Canadian Journal of Infectious Diseases and Medical Microbiology
- Vol. 2026 (1)
Open AccessKSHV Seropositivity Associates With Impaired Immune Reconstitution in Virally Suppressed HIV
Background: Kaposi’s sarcoma–associated herpesvirus (KSHV) seropositivity is prevalent in people with HIV (PWH), yet its association with immune reconstitution during long‐term ART remains unclear. Methods: In this retrospective cohort study, we reviewed the records of 209 virally suppressed PWH (VL < 50 copies/mL) after ≥ 2 years of ART. Participants were stratified based on their KSHV serostatus (IgG+). Data on immune parameters were extracted from laboratory reports corresponding to the 2‐year post‐ART time point. Results: KSHV seropositive individuals exhibited significantly lower CD4 + counts (101.5 vs. 316.0 cells/μL; p < 0.001), reduced CD4/CD8 ratios (0.26 vs. 0.60; p < 0.001), and elevated IL‐6 (9.78 vs. 5.46 pg/mL; p < 0.001). Multivariate analysis identified IL‐6 as an independent predictor of seropositivity (OR = 1.238; p < 0.001). The combination of CD4 + (≤ 126 cells/μL) and IL‐6 (> 5.83 pg/mL) showed superior diagnostic accuracy for KSHV seropositivity (AUC = 0.832). Conclusion: KSHV seropositivity correlates with impaired immune reconstitution in virally suppressed PWH. CD4 + and IL‐6 may jointly serve as a screening tool for KSHV serostatus assessment, though their utility for detecting active infection requires further study.
- Open Access
Therapeutic Efficacy of an Anti-P116-661 Polyclonal Antibody Against Mycoplasma pneumoniae Infection
The aim of this study was to investigate the therapeutic potential of a polyclonal antibody against the Mycoplasma pneumoniae (MP) P116-661 protein. A polyclonal antibody against the P116-661 protein was obtained by immunizing New Zealand white rabbits, and its therapeutic effects were systematically evaluated by various experimental methods. An immunofluorescence assay was used to detect the inhibitory effect of the P116-661 polyclonal antibody on the adhesion of MP cells to A549 cells. ELISAs and Western blotting were used to analyze the expression levels of inflammatory factors, such as IL-6 and TNF-α, in Beas-2b cells and model mice after MP infection. HE staining was used to observe pathological changes in the lung tissue of the infected mice. The results showed that the P116-661 polyclonal antibody effectively inhibited the adhesion of MP cells to A549 cells. It significantly reduced the secretion levels of inflammatory factors, such as IL-6 and TNF-α, in Beas-2b cells and mice after MP infection. Moreover, the antibody significantly improved the pathological damage to the lungs that was caused by MP infection in mice. This study confirms that the P116-661 polyclonal antibody has good therapeutic effects in vitro and in vivo, providing a new experimental basis for immunotherapy against MP infection.
Open AccessTherapeutic Efficacy of an Anti-P116-661 Polyclonal Antibody Against Mycoplasma pneumoniae Infection
The aim of this study was to investigate the therapeutic potential of a polyclonal antibody against the Mycoplasma pneumoniae (MP) P116-661 protein. A polyclonal antibody against the P116-661 protein was obtained by immunizing New Zealand white rabbits, and its therapeutic effects were systematically evaluated by various experimental methods. An immunofluorescence assay was used to detect the inhibitory effect of the P116-661 polyclonal antibody on the adhesion of MP cells to A549 cells. ELISAs and Western blotting were used to analyze the expression levels of inflammatory factors, such as IL-6 and TNF-α, in Beas-2b cells and model mice after MP infection. HE staining was used to observe pathological changes in the lung tissue of the infected mice. The results showed that the P116-661 polyclonal antibody effectively inhibited the adhesion of MP cells to A549 cells. It significantly reduced the secretion levels of inflammatory factors, such as IL-6 and TNF-α, in Beas-2b cells and mice after MP infection. Moreover, the antibody significantly improved the pathological damage to the lungs that was caused by MP infection in mice. This study confirms that the P116-661 polyclonal antibody has good therapeutic effects in vitro and in vivo, providing a new experimental basis for immunotherapy against MP infection.
- 8 May 2023
- Published by Wiley in Journal of Medical Virology
- Vol. 95 (5) , e28776
A comprehensive overview on the transmission, pathogenesis, diagnosis, treatment, and prevention of SARS‐CoV‐2
Severe acute respiratory syndrome coronavirus (SARS‐CoV) is a single positive‐strand RNA virus that is responsible for the current pandemic that the world has been facing since 2019. The primary route of transmission of SARS‐CoV‐2 is through respiratory tract transmission. However, other transmission routes such as fecal‐oral, vertical transmission, and aerosol‐eye also exist. In addition, it has been found that the pathogenesis of this virus involves the binding of the virus's S protein to its host cell surface receptor angiotensin‐converting enzyme 2, which results in the subsequent membrane fusion that is required for SARS‐CoV‐2 to replicate and complete its entire life. The clinical symptoms of patients infected with SARS‐CoV‐2 can range from asymptomatic to severe. The most common symptoms seen include fever, dry cough, and fatigue. Once these symptoms are observed, a nucleic acid test is done using reverse transcription‐polymerase chain reaction. This currently serves as the main confirmatory tool for COVID‐19. Despite the fact that no cure has been found for SARS‐CoV‐2, prevention methods such as vaccines, specific facial mask, and social distancing have proven to be quite effective. It is imperative to have a complete understanding of the transmission and pathogenesis of this virus. To effectively develop new drugs as well as diagnostic tools, more knowledge about this virus would be needed.
- 8 May 2023
- Published by Wiley in Journal of Medical Virology
- Vol. 95 (5) , e28776
A comprehensive overview on the transmission, pathogenesis, diagnosis, treatment, and prevention of SARS‐CoV‐2
Severe acute respiratory syndrome coronavirus (SARS‐CoV) is a single positive‐strand RNA virus that is responsible for the current pandemic that the world has been facing since 2019. The primary route of transmission of SARS‐CoV‐2 is through respiratory tract transmission. However, other transmission routes such as fecal‐oral, vertical transmission, and aerosol‐eye also exist. In addition, it has been found that the pathogenesis of this virus involves the binding of the virus's S protein to its host cell surface receptor angiotensin‐converting enzyme 2, which results in the subsequent membrane fusion that is required for SARS‐CoV‐2 to replicate and complete its entire life. The clinical symptoms of patients infected with SARS‐CoV‐2 can range from asymptomatic to severe. The most common symptoms seen include fever, dry cough, and fatigue. Once these symptoms are observed, a nucleic acid test is done using reverse transcription‐polymerase chain reaction. This currently serves as the main confirmatory tool for COVID‐19. Despite the fact that no cure has been found for SARS‐CoV‐2, prevention methods such as vaccines, specific facial mask, and social distancing have proven to be quite effective. It is imperative to have a complete understanding of the transmission and pathogenesis of this virus. To effectively develop new drugs as well as diagnostic tools, more knowledge about this virus would be needed.
- 17 August 2022
- Published by Wiley in Journal of Medical Virology
- Vol. 94 (12) , 6016-6022
Seroprevalence of Kaposi's sarcoma‐associated herpesvirus and risk factors in Jiuquan area, China
The seroprevalence of Kaposi's sarcoma‐associated herpesvirus (KSHV) is high in Xinjiang, China. But the seroprevalence of KSHV and risk factors are still unknown in Gansu which is adjacent to Xinjiang. Six hundred and seventy‐eight serum samples of the general population and 87 serum samples of syphilis patients from Jiuquan, Gansu were tested for antibodies against KSHV, including one latent protein (ORF73) and two lytic proteins (ORF65 and K8.1) using the ELISA. The total KSHV‐seropositive rate was 15.9% in 678 serum samples in the Jiuquan area, and the KSHV‐seropositive rate of males was higher than females (18.0% vs. 14.6%, p > 0.05). The Uygur, Kazakh, Hui, Manchu, and Mongolian populations had a higher seroprevalence of KSHV than the Han population (43.8%, 40.0%, 34.5%, 30.3%, 35.0% vs. 11.0%, respectively) among the ethnic groups in Jiuquan. Compared to the Han, Uygur, Kazak, Hui, Manchu, and Mongolian people had an increase in the risk of KSHV of 528.9%, 439.1%, 325.6%, 251.6%, and 335.4% (p < 0.001, p < 0.001, p < 0.001, p = 0.002, p = 0.003, respectively). The serum prevalence of KSHV in subjects aged < 20 years, 20−50 years, and >50 years was 13.8%, 14.7%, and 20.1%, respectively. Compared to the subjects aged < 20 years, 20−50 years and >50 years had an increase in the risk of KSHV of 7.4% and 56.9% (p = 0.829 and p = 0.204, respectively). Compared to the positive rate of KSHV in the general population of Anhui, the positive rate of KSHV was significantly higher in the general population of the Jiuquan area (15.9% vs. 9%, p < 0.01). There was no significant difference in the positive rate of KSHV between the Han population of Jiuquan and the Han population of Anhui (p > 0.05). In the population of syphilis patients in the Jiuquan area, the positive rate of KSHV was 30.7%, which was higher than that of the general population in the Gansu area (p < 0.05). This study indicates that Gansu has a high seroprevalence of KSHV. Ethnicity and syphilis are risk factors for KSHV infection.
- 17 August 2022
- Published by Wiley in Journal of Medical Virology
- Vol. 94 (12) , 6016-6022
Seroprevalence of Kaposi's sarcoma‐associated herpesvirus and risk factors in Jiuquan area, China
The seroprevalence of Kaposi's sarcoma‐associated herpesvirus (KSHV) is high in Xinjiang, China. But the seroprevalence of KSHV and risk factors are still unknown in Gansu which is adjacent to Xinjiang. Six hundred and seventy‐eight serum samples of the general population and 87 serum samples of syphilis patients from Jiuquan, Gansu were tested for antibodies against KSHV, including one latent protein (ORF73) and two lytic proteins (ORF65 and K8.1) using the ELISA. The total KSHV‐seropositive rate was 15.9% in 678 serum samples in the Jiuquan area, and the KSHV‐seropositive rate of males was higher than females (18.0% vs. 14.6%, p > 0.05). The Uygur, Kazakh, Hui, Manchu, and Mongolian populations had a higher seroprevalence of KSHV than the Han population (43.8%, 40.0%, 34.5%, 30.3%, 35.0% vs. 11.0%, respectively) among the ethnic groups in Jiuquan. Compared to the Han, Uygur, Kazak, Hui, Manchu, and Mongolian people had an increase in the risk of KSHV of 528.9%, 439.1%, 325.6%, 251.6%, and 335.4% (p < 0.001, p < 0.001, p < 0.001, p = 0.002, p = 0.003, respectively). The serum prevalence of KSHV in subjects aged < 20 years, 20−50 years, and >50 years was 13.8%, 14.7%, and 20.1%, respectively. Compared to the subjects aged < 20 years, 20−50 years and >50 years had an increase in the risk of KSHV of 7.4% and 56.9% (p = 0.829 and p = 0.204, respectively). Compared to the positive rate of KSHV in the general population of Anhui, the positive rate of KSHV was significantly higher in the general population of the Jiuquan area (15.9% vs. 9%, p < 0.01). There was no significant difference in the positive rate of KSHV between the Han population of Jiuquan and the Han population of Anhui (p > 0.05). In the population of syphilis patients in the Jiuquan area, the positive rate of KSHV was 30.7%, which was higher than that of the general population in the Gansu area (p < 0.05). This study indicates that Gansu has a high seroprevalence of KSHV. Ethnicity and syphilis are risk factors for KSHV infection.
- Open Access
- 25 February 2022
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 13, 825111
Recovery Infectious Enterovirus 71 by Bac-to-Bac Expression System in vitro and in vivo
Enterovirus 71 (EV71) is one of the most important etiological agents for hand–foot–mouth disease. Compared with coxsackievirus A16 infection, EV71 infection is often associated with severe central nervous system complications, such as encephalitis, encephalomyelitis, and acute flaccid paralysis in infants and young children. In this study, we constructed a recombinant baculovirus with T7 ribonucleic acid polymerase under the control of a cytomegalovirus promoter and simultaneously engineered the T7 promoter upstream of a full-length EV71 complementary deoxyribonucleic acid. After transduction into mammalian cells, typical cytopathic effects (CPEs) and VP1 signals were detected in cells transfected with recombinant baculovirus. Additionally, viral particles located in the cytoplasm of human rhabdomyosarcoma cells (Rd) and Vero cells were observed by electron microscope, indicating that EV71 was recovered using a Bac-to-Bac expression system in vitro. After four passages, the rescued virus had a growth curve and plaque morphology similar to those of the parental virus. Furthermore, the Vp1 gene and the protein from the mouse brain were detected by reverse transcription polymerase chain reaction and immunohistochemistry after intracerebral injection of purified recombinant baculovirus. Typical CPEs were observed after inoculation of the supernatant from mouse brain to Rd cells, revealing a reconstruction of EV71 in vivo. Thus, we established a new approach to rescue EV71 based on a baculovirus expression system in vitro and in vivo, which may provide a safe and convenient platform for fundamental research and a strategy to rescue viruses that currently lack suitable cell culture and animal models.
- 25 February 2022
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 13, 825111
Open AccessRecovery Infectious Enterovirus 71 by Bac-to-Bac Expression System in vitro and in vivo
Enterovirus 71 (EV71) is one of the most important etiological agents for hand–foot–mouth disease. Compared with coxsackievirus A16 infection, EV71 infection is often associated with severe central nervous system complications, such as encephalitis, encephalomyelitis, and acute flaccid paralysis in infants and young children. In this study, we constructed a recombinant baculovirus with T7 ribonucleic acid polymerase under the control of a cytomegalovirus promoter and simultaneously engineered the T7 promoter upstream of a full-length EV71 complementary deoxyribonucleic acid. After transduction into mammalian cells, typical cytopathic effects (CPEs) and VP1 signals were detected in cells transfected with recombinant baculovirus. Additionally, viral particles located in the cytoplasm of human rhabdomyosarcoma cells (Rd) and Vero cells were observed by electron microscope, indicating that EV71 was recovered using a Bac-to-Bac expression system in vitro. After four passages, the rescued virus had a growth curve and plaque morphology similar to those of the parental virus. Furthermore, the Vp1 gene and the protein from the mouse brain were detected by reverse transcription polymerase chain reaction and immunohistochemistry after intracerebral injection of purified recombinant baculovirus. Typical CPEs were observed after inoculation of the supernatant from mouse brain to Rd cells, revealing a reconstruction of EV71 in vivo. Thus, we established a new approach to rescue EV71 based on a baculovirus expression system in vitro and in vivo, which may provide a safe and convenient platform for fundamental research and a strategy to rescue viruses that currently lack suitable cell culture and animal models.
- Open Access
- 31 December 2021
- Published by Wiley in Canadian Journal of Infectious Diseases and Medical Microbiology
- Vol. 2021, 1-8
Prevalence and Risk Factors of Kaposi’s Sarcoma-Associated Herpesvirus Infection among Han and Uygur Populations in Xinjiang, China
Kaposi’s sarcoma-associated herpesvirus (KSHV) is the causative agent of Kaposi’s sarcoma (KS), which is endangering human health worldwide, especially in Africa, Europe, the United States, and parts of Asia. The aim of this study was to investigate the prevalence of KSHV in Xinjiang. Three KSHV recombinant proteins (ORF65, ORF73, and K8.1) were used to detect KSHV infection. The serum samples to be tested were detected by an indirect ELISA method. The overall infection rate of KSHV in Xinjiang was 25.60%, with a higher infection rate in the Uygur population of 29.79%. After adjusting for possible confounders, Uygur (OR = 3.95, 95% CI 2.64–6.12, ), agriculture and livestock (OR = 1.60, 95% CI 1.20–2.17, = 0.002), age ≤ 50 years (OR = 1.50, 95% CI 1.13–2.00, = 0.006), and predominantly meat-based diet (OR = 1.72, 95% CI 1.11–2.78, = 0.018) were significantly associated with the odds of KSHV seropositivity correlation. Three unique sequences of KSHV were obtained in this study; genotypic analysis showed that the three unique sequences were all subtype A2.
- 31 December 2021
- Published by Wiley in Canadian Journal of Infectious Diseases and Medical Microbiology
- Vol. 2021, 1-8
Open AccessPrevalence and Risk Factors of Kaposi’s Sarcoma-Associated Herpesvirus Infection among Han and Uygur Populations in Xinjiang, China
Kaposi’s sarcoma-associated herpesvirus (KSHV) is the causative agent of Kaposi’s sarcoma (KS), which is endangering human health worldwide, especially in Africa, Europe, the United States, and parts of Asia. The aim of this study was to investigate the prevalence of KSHV in Xinjiang. Three KSHV recombinant proteins (ORF65, ORF73, and K8.1) were used to detect KSHV infection. The serum samples to be tested were detected by an indirect ELISA method. The overall infection rate of KSHV in Xinjiang was 25.60%, with a higher infection rate in the Uygur population of 29.79%. After adjusting for possible confounders, Uygur (OR = 3.95, 95% CI 2.64–6.12, ), agriculture and livestock (OR = 1.60, 95% CI 1.20–2.17, = 0.002), age ≤ 50 years (OR = 1.50, 95% CI 1.13–2.00, = 0.006), and predominantly meat-based diet (OR = 1.72, 95% CI 1.11–2.78, = 0.018) were significantly associated with the odds of KSHV seropositivity correlation. Three unique sequences of KSHV were obtained in this study; genotypic analysis showed that the three unique sequences were all subtype A2.
- Open Access
- 7 December 2021
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 8, 628370
A Review of SARS-CoV2: Compared With SARS-CoV and MERS-CoV
The outbreak of coronavirus disease 2019 (COVID-19) has been spreading rapidly in China and the Chinese government took a series of policies to control the epidemic. Studies found that severe COVID-19 is characterized by pneumonia, lymphopenia, exhausted lymphocytes and a cytokine storm. Studies have showen that SARS-CoV2 has significant genomic similarity to the severe acute respiratory syndrome (SARS-CoV), which was a pandemic in 2002. More importantly, some diligent measures were used to limit its spread according to the evidence of hospital spread. Therefore, the Public Health Emergency of International Concern (PHEIC) has been established by the World Health Organization (WHO) with strategic objectives for public health to curtail its impact on global health and economy. The purpose of this paper is to review the transmission patterns of the three pneumonia: SARS-CoV2, SARS-CoV, and MERS-CoV. We compare the new characteristics of COVID-19 with those of SARS-CoV and MERS-CoV.
- 7 December 2021
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 8, 628370
Open AccessA Review of SARS-CoV2: Compared With SARS-CoV and MERS-CoV
The outbreak of coronavirus disease 2019 (COVID-19) has been spreading rapidly in China and the Chinese government took a series of policies to control the epidemic. Studies found that severe COVID-19 is characterized by pneumonia, lymphopenia, exhausted lymphocytes and a cytokine storm. Studies have showen that SARS-CoV2 has significant genomic similarity to the severe acute respiratory syndrome (SARS-CoV), which was a pandemic in 2002. More importantly, some diligent measures were used to limit its spread according to the evidence of hospital spread. Therefore, the Public Health Emergency of International Concern (PHEIC) has been established by the World Health Organization (WHO) with strategic objectives for public health to curtail its impact on global health and economy. The purpose of this paper is to review the transmission patterns of the three pneumonia: SARS-CoV2, SARS-CoV, and MERS-CoV. We compare the new characteristics of COVID-19 with those of SARS-CoV and MERS-CoV.
- Open Access
- 17 December 2020
- Published by Wiley in Journal of Medical Virology
- Vol. 93 (5) , 2857-2866
Evaluation of serum IgM and IgG antibodies in COVID‐19 patients by enzyme linked immunosorbent assay
Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is sweeping the world since the end of 2019. The titer change of antibodies against SARS‐CoV‐2 needs to be further clarified, the clinical and preventive value of antibodies still needs to be further investigated. An enzyme‐linked immunosorbent assay (ELISA) was established by coating with SARS‐CoV‐2 recombinant spike protein and used to detect serum immunoglobulin M (IgM) and immunoglobulin G (IgG) antibodies against SARS‐CoV‐2 in coronavirus disease 2019 patients to evaluate the pattern of changes of antibodies. The specificity of the ELISA for detection SARS‐CoV‐2 IgM and IgG were 96% (144/150) and 100% (150/150), respectively. The sensitivity of ELISA was 100% (150/150) for IgM, and 99.3% (149/150) for IgG. SARS‐CoV‐2‐SP‐IgM and SP‐IgG antibodies could be detected on Day 1 of hospitalization in 12.5% patients, and SP‐IgM began to decrease after reaching its peak at around 22–28 days, and become negative at Month 3 in 30% patients and negative at Month 7 in 79% of these patients after onset; IgG reached its peak around Day 22–28 and kept at a high level within the longest observation period for 4 months, it dropped very sharply at 7 months. The positive rates of SP‐IgM and SP‐IgG were higher than those of reverse transcription‐polymerase chain reaction on Day 7 and 4. The established indirect ELISA has good specificity and sensitivity. IgM and IgG against SARS‐CoV‐2 appeared almost simultaneously in the early stage, and the level of IgG antibodies could not maintain a high plateau in the observation period of 7 months. Our data will help develop the diagnosis and vaccine of SARS‐CoV‐2.
- 17 December 2020
- Published by Wiley in Journal of Medical Virology
- Vol. 93 (5) , 2857-2866
Open AccessEvaluation of serum IgM and IgG antibodies in COVID‐19 patients by enzyme linked immunosorbent assay
Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is sweeping the world since the end of 2019. The titer change of antibodies against SARS‐CoV‐2 needs to be further clarified, the clinical and preventive value of antibodies still needs to be further investigated. An enzyme‐linked immunosorbent assay (ELISA) was established by coating with SARS‐CoV‐2 recombinant spike protein and used to detect serum immunoglobulin M (IgM) and immunoglobulin G (IgG) antibodies against SARS‐CoV‐2 in coronavirus disease 2019 patients to evaluate the pattern of changes of antibodies. The specificity of the ELISA for detection SARS‐CoV‐2 IgM and IgG were 96% (144/150) and 100% (150/150), respectively. The sensitivity of ELISA was 100% (150/150) for IgM, and 99.3% (149/150) for IgG. SARS‐CoV‐2‐SP‐IgM and SP‐IgG antibodies could be detected on Day 1 of hospitalization in 12.5% patients, and SP‐IgM began to decrease after reaching its peak at around 22–28 days, and become negative at Month 3 in 30% patients and negative at Month 7 in 79% of these patients after onset; IgG reached its peak around Day 22–28 and kept at a high level within the longest observation period for 4 months, it dropped very sharply at 7 months. The positive rates of SP‐IgM and SP‐IgG were higher than those of reverse transcription‐polymerase chain reaction on Day 7 and 4. The established indirect ELISA has good specificity and sensitivity. IgM and IgG against SARS‐CoV‐2 appeared almost simultaneously in the early stage, and the level of IgG antibodies could not maintain a high plateau in the observation period of 7 months. Our data will help develop the diagnosis and vaccine of SARS‐CoV‐2.